Evaluation of Hepatic 11 β-Hydroxysteroid Dehydrogenase Activity by Cortisone Acetate Test in Young Adults With Diabetes Mellitus Type 1

K. ŠIMŮNKOVÁ¹², R. HAMPL¹, M. HILL¹, L. KŘÍŽ¹, J. VRBÍKOVA¹, H. KVÁSNÍČKOVA¹, K. VONDRA¹

¹Institute of Endocrinology, Prague, Czech Republic, ²Third Department of Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic

Received September 6, 2010
Accepted October 8, 2010
On-line November 29, 2010

Summary
Cortisone acetate test was performed in twelve young adult patients with diabetes mellitus type 1, after dexamethasone administration to suppress endogenous cortisol production. Previous screening revealed that all of the subjects had peak cortisol responses in the range from subnormal to normal, as determined by a low-dose Synacthen test. The aim was to find out whether these patients would exhibit different conversion of cortisone to cortisol by 11β-hydroxysteroid dehydrogenase. Using multifactorial ANOVA the following significant relationships were obtained between cortisol or cortisol/cortisone ratio measured during the test and other parameters examined a) before dexamethasone suppression and b) during the test: a) Cortisol at 120th minute negatively correlated with daily insulin dose and positively with basal aldosterone. Cortisol/cortisone ratio at 60th, 120th, 180th, and 240th minute negatively correlated with basal aldosterone/plasma renin activity ratio, urinary free cortisol/24 hours and positively with basal dehydroepiandrosterone sulphate. b) Cortisol at 120th minute negatively correlated with suppressed basal serum glycemia; cortisol/cortisone ratio during the whole test negatively correlated with suppressed basal ACTH. The examination of peripheral metabolism of cortisol using cortisone acetate test in patients with diabetes mellitus type 1 showed adaptive changes of 11β-hydroxysteroid dehydrogenase activity associated with altered cortisol tissue supply.

Key words
Cortisone • Cortisol • Cortisone acetate test • Peripheral metabolism of glucocorticoids • Diabetes mellitus

Corresponding author
K. Šimůnková, Third Department of Medicine, First Faculty of Medicine, Charles University, U Nemocnice 1, 128 21 Prague 2, Czech Republic. Fax: +420 224 905 325. E-mail: ksimunkova@endo.cz

Introduction
In our recent cross-sectional study of young adults with well controlled diabetes mellitus type 1 (DM1) we found in approximately one fourth of patients a decreased peak response of serum cortisol (F) during low-dose Synacthen test (LDST) (Šimůnková et al. 2010). The fact that no significant differences in metabolic control or daily dose of insulin in this group of low responders in LDST were present suggests that peripheral metabolism of F at the time of the study might compensate subnormal F response. One of the possible mechanism could be changes in 11β-hydroxysteroid dehydrogenase (11β-HSD1) activity, responsible for conversion of inactive cortisone (E) to active F (Reichardt et al. 2000). Local F is involved in regulation of a number of metabolic processes (Tomlinson et al. 2004, Filipovic et al. 2008). In the major metabolising tissues F bioavailability substantially influences glycoregulation; in liver it is primarily its effect on insulin action and intensity of gluconeogenesis (Reynolds et al. 2003, Putignano et al. 2004).

Therefore we focused on the follow up of 11β-HSD1 activity in DM1 patients. In agreement with other authors, the activity of 11β-HSD1, namely its liver
isoenzyme, was assessed by cortisone acetate test, believed to provide sufficient information for clinical research (Andrews et al. 2002, Rask et al. 2002, Westerbacka et al. 2003, Tomlinson et al. 2004, Putignano et al. 2004, Stewart et al. 2005, Mai et al. 2007).

The aim was to find out whether various cortisol response in LDST observed in our young adult DM1 patients is associated with the changes of conversion of E to F. Multifactorial ANOVA was applied for evaluation of contribution of additional clinical and laboratory parameters on 11β-HSD1 activity.

Subjects and Methods

Subjects

Twelve young adults with well controlled DM1 with a different peak F response during LDST (range 438-760 nmol/l, normal response >500 nmol/l) were studied. There were 7 women and 5 men (range 30-42 years), duration of DM1 was 14±5.6 years (mean ± S.D.), DM1 onset 26±4.8 years, body mass index (BMI) 24.2±3.2 %, glycosylated hemoglobin (HbA1C) 7.3±1.6 %, daily insulin dose (IU/kg/day) 0.6±0.16. Their hormonal characteristics were: plasma renin activity (PRA) 0.45±0.24 ng/ml, urinary free cortisol/24 hours (UFC/24h) 24±3.2 %, glycosylated hemoglobin (HbA1C) 7.3±1.6 %, daily insulin dose (IU/kg/day) 0.6±0.16. Their hormonal characteristics were: plasma renin activity (PRA) 0.45±0.24 ng/ml, urinary free cortisol/24 hours (UFC/24h) 24±3.2 %, dehydroepiandrosterone sulphate (DHEA-S) (women only) 2.64±1.65 μmol/l, aldosterone (aldo) 0.11±0.06 nmol/l.

The following week after LDST the patients underwent at first dexametasone (dexa) suppression and on the following day they were subjected to cortisone acetate test. Fasting values of F, ACTH and plasma glucose levels before and after dexamethasone application are shown in Table 1.

Test protocol

On the first day (Day 1), blood was withdrawn at 8:00 after overnight fasting from the patients and healthy subjects for determination of F, E, ACTH, alo, PRA, DHEA-S, HbA1C, and blood glucose. The urine was also collected for determination of urinary free F during 24 hours (UFC/24h). At 23:00 on the Day 1, they were given 1 mg dexa orally to suppress endogenous F production. All the subjects reattended the Institute at 7:30 on the following morning and blood was withdrawn again at 8:00 (time 0) for determination of basal levels of F, E, ACTH and plasma glucose. They were then given cortisone acetate (25 mg) orally (Kortison Cyba Novartis) and blood samples were collected at 30 min intervals using intravenous cannula, i.e. after 30th, 60th, 90th, 120th, 180th and 240th min for determination of serum F, E and glucose. The blood samples for PRA determination were immediately placed into iced-cooled water bath.

Thirty minutes after sample collection, blood was centrifuged at 3000 rpm for 15 min and serum was

### Table 1. Fasting values of cortisol, ACTH and glucose in serum before (Day1) and after (Day 2) dexametasone aplication.

| Variables                  | Day 1 |        | Day 2 |        |
|----------------------------|-------|--------|-------|--------|
|                            | median | upper quartile | lower quartile | median | upper quartile | lower quartile |
| Cortisol (nmol/l)          | 323    | 274    | 494   | 59     | 44   | 93   |
| ACTH (ng/l)                | 21     | 14     | 29    | 3.7    | 3.0  | 4.2  |
| Glucose in serum (mmol/l)  | 6.5    | 4.1    | 9.0   | 13.1   | 10.4 | 13.3 |
collected into plastic tubes. Samples were frozen at -20 °C and stored at this temperature until analyzed.

The protocol was approved by the Ethical Committee of the Institute of Endocrinology. All the subjects signed the informed consent.

Methods for steroid determination

A high performance liquid chromatography (HPLC) system (Dionex Softron, Germering, Germany) was used for separation of cortisol from cortisone and for their quantification. It consisted of a HPLC pump system P 680 equipped with automatic flow rate control, automated sample injector ASI-100, thermostated column compartment TCC-100 and photodiode array detector PDA-100 with wavelength range 190-600 nm. A speed-vacuum centrifuge (HETO, Melsungen, Germany) was used for solvent evaporation. Serum cortisol and cortisone concentrations were determined by a method using high HPLC with UV/VIS detection after solvent extraction and partitioning as follows:

Serum sample (200 µl) was diluted with buffer (200 µl) and 11β-hydroxy-4-androstene-3, 17-dione (40 ng per sample) was added as an internal standard. The samples were extracted twice with diethyl ether (2 ml) for 1 min and aqueous phase was frozen. The organic phase containing steroids was decanted and evaporated under a stream of nitrogen. To avoid possible column contamination from free fatty acids, the dry residue from the extract was dissolved in 80 % aqueous methanol (1 ml, v/v) and n-hexane (1 ml). The mixture was extracted again for 1 min. N-hexane-containing phase was removed and discarded. The residual polar phase was evaporated. If the sample was held at 55 °C and the dry residue was dissolved in 15 % acetonitrile (50 µl, v/v) and mixed vigorously to rinse the tube walls. The samples were then centrifuged (2000 g, 3 min, 22 °C) and decanted solution transferred into vials. Simultaneously, blank samples and quality control samples were processed in the same way to avoid possible contamination and to determine procedural losses of individual metabolites.

HPLC separation

Standard mixtures of cortisol and cortisone in the following concentrations were used for calibration by an external standard method: cortisone (25, 50, 100, 250, 500, 625 and 750 pg/µl), cortisol (100, 250, 500, 750, 1500, 2250 and 3000 pg/µl). HPLC separation was carried out using reverse phase Macherey-Nagel EC 250/4 nucleosil 100-5 C18 column (250 x 4 mm) with particle size of 5 µm (Macherey-Nagel, Dueren, Germany). The following protocol was used: Elution gradient: 0.0-2.1 min constant mobile phase acetonitrile-water (15:85), 2.1-12.0 min, linear gradient from methanol-acetonitrile-water (40:9:51) to methanol-acetonitrile-water (49:11.3:39.7), 12.0-15.0 min, constant mobile phase methanol (100 %), 15.0-19.0, constant mobile phase acetonitrile-water (15:85).

The temperature in the column compartment was 35 °C and the flow rate of the mobile phase was kept constant at 0.8 ml/min. Under these conditions the retention times of authentic cortisone and cortisol standards were 12.13 min and 12.84 min, respectively. The PDA-100 detector response was recorded in UV mode at 239 nm for cortisone and 243 nm for cortisol at the appropriate retention times. Cortisone and cortisol contents were determined according to a calibration curve and the values were corrected for procedural and extraction losses according to yields of internal standard.

PRA was estimated by determination of angiotensin I using RIA kit from Immunotech (Marseille, France, Czech Division, Prague, Czech Republic). The detection limit for PRA was 0.1 ng/ml. Intra-assay and inter-assay c.v. were 10.4 and 10.5 %, physiological range 0.50-1.90 ng/ml/h.

Plasma ACTH was determined by IRMA kit from Immunotech in keeping with the manufacturer instructions. The detection limit was 1.2 pg/ml, intra-assay and inter-assay c.v. were 9.1 and 9.6 %, physiological range 1.0-50.0 ng/l.

Serum aldo was determined by RIA kit from Immunotech after extraction into dichloromethane. Intra- and inter assay c.v. were 7.8 and 8.4 %, physiological range (nmol/l): 0.01-0.50.

DHEA-S was determined by RIA kit from Immunotech after extraction into dichloromethane. Intra- and inter assay c.v. were 4.2 and 7.2 %, physiological range (µmol/l): Females 30-40 years 1.80-9.70, 40-50 years 0.66-7.20.

UFC (free urinary cortisol) was determined by RIA kit from Orion Diagnostica (Finland). Intra-assay and inter-assay c.v. were 3.8 and 4.4 %, physiological range 38-208 nmol/24hours.

Methods for determination of metabolic parameters

Plasma glucose was measured by glucos oxidase methods on Glucose analyser; Beckman, Fullerton, CA, physiological range 3.9-5.5 mmol/l.

HbA1C was determined by immunochemical methods using quantitative immunoturbidimetry
standardized by IFCC (Roche Diagnostics GmbH, Mannheim, Germany) on Integra 400 analyser (Roche Diagnostics GmbH, Mannheim, Germany). Intra-assay and inter-assay c.v. were 5.9 and 3.8 %, physiological range below 4.5 % according IFCC.

Statistics

Repeated measures ANOVA model followed by least significant difference multiple comparisons were used for evaluation of cortisol profile on stage of the experiment and status of the subjects. The model consisted of the between-subject factor Status (controls, diabetics), subject factor and within-subject factor and Time (0, 30, 60, 90, 120, 180, 240 min). For evaluation of Gaussian data distribution, the skewness and kurtosis z-score tests were applied. No data transformation was required. Multifactorial ANOVA: Relationships between F, and F to E ratios and indices of relevant parameters bidirectionally were evaluated by Orthogonal Projections to Latent Structures.

Results

Concentration of cortisol after cortisone acetate administration (Fig. 1)

After administration of cortisone acetate in DM1 and H in the first 60th minutes concentration of F in the serum increased to practically the same levels. After 60th minutes, the levels of serum F decreased fast down to 211 nmol/l (median) in 240th minute in H, while in DM1 concentration of F continued to rise until the 120th minute. After 120 minutes, a slow decrease occurred even in this group (down) to 346 nmol/l in the 240th minute.

From the 60th minute, concentration of F in both groups was significantly different. During the whole test, levels of F remained higher in DM1 with significance p<0.05.

Multifactorial ANOVA

Values of F and F/E ratios obtained during cortisone acetate test were analyzed by multifactorial ANOVA against:

1. peak F response in serum from previous LDST;

2. fasting non-supressed values of ACTH, F, DHEA-S in women, PRA, aldo, aldo/PRA, glucose, IU/kg/24 hours, UFC/24 hours in serum from Day 1 (measured before suppression by dexta);

3. fasting suppressed values F, E, ACTH and glucose in serum from Day 2 (measured after suppression by dexta during the test).

The results of the analysis are shown in Table 2 and 3. The following significant relationships were obtained:

Ad 1) no significant relations were found.

Ad 2) Cortisol at 120th minute negatively correlated with daily insulin dose and positively with basal aldosterone. Cortisol/cortisone ratio at 60th, 120th, 180th, and 240th minute negatively correlated with basal aldosterone/plasma renin activity ratio, urinary free cortisol/24 hours and positively with basal dehydroepiandrosterone sulphate.

Ad 3) Cortisol at 120th minute negatively correlated with suppressed basal serum glycemia; cortisol/cortisone ratio during the whole test negatively correlated with suppressed basal ACTH.

Fig. 1. Concentration of serum cortisol during cortisone acetate test. The empty circles and filled circles symbolize the means for individual stages of the test for diabetics (filled circles) and healthy subjects (empty circles), respectively. The error bars symbolize 95 % confidence intervals for the means as computed using least significant difference multiple comparisons. The groups with non-overlapping 95 % confidence intervals are statistically significant (p<0.05). The significances of the factors (A, B, C) and between-factor interaction A×B were as follows: Group (A): F=26.64, p<0.0001; Time (B): F=32.72, p<0.0001; Subject (C): F=8.58, p<0.0001; A × B: F=3.13, p=0.0028; F..Fisher's statistics; p..significance level.
Table 2. Relationship between cortisol in 120th min and indices of relevant parameters as evaluated by bidirectional orthogonal projections to latent structures.

| Variables                        | Parameter (component loading) | 95% Confidence interval | 99% Confidence interval | Parameter/95% CI | Parameter/99% CI | Correlation with the predictive component | Significance of the parameters |
|----------------------------------|-------------------------------|--------------------------|--------------------------|-----------------|-----------------|------------------------------------------|-------------------------------|
| Cortisol, 120 min                | 1.000                         | 0.363                    | 0.575                    | 2.75            | 1.74            | 0.877                                    | p<0.01                        |
| Ins/kg/day                       | -0.542                        | 0.501                    | 0.792                    | -1.08           | -0.68           | -0.687                                   | p<0.05                        |
| Aldosterone                      | 0.559                         | 0.328                    | 0.518                    | 4.58            | 2.89            | 0.734                                    | p<0.01                        |
| Basal serum glucose after dexam   | -0.654                        | 0.194                    | 0.307                    | -4.08           | -2.58           | -0.825                                   | p<0.01                        |

$R^2_{a)}$ 76.9 %  
$Q^2_{b)}$ 65.9%

$^a$R$^2$ is the percent of variation of dependent variable explained by the model; $^b$Q$^2$ is the percent of variation of dependent variable predicted by the model according to cross validation; the model was created from all steroids and related substances investigated but only the relevant independent variables remained in the final model (for details see Statistical data analysis).

Table 3. Relationship between cortisone and indices of relevant parameters as evaluated by bidirectional orthogonal projections to latent structures.

| Variables                        | Parameter (component loading) | 95% Confidence interval | 99% Confidence interval | Parameter/95% CI | Parameter/99% CI | Correlation with the predictive component | Significance of the parameters |
|----------------------------------|-------------------------------|--------------------------|--------------------------|-----------------|-----------------|------------------------------------------|-------------------------------|
| Cortisone, 60 min                | 0.489                         | 0.413                    | 0.653                    | 1.18            | 0.75            | 0.704                                    | p<0.05                        |
| Cortisone, 120 min               | 0.526                         | 0.581                    | 0.920                    | 0.90            | 0.57            | 0.723                                    | NS                            |
| Cortisone, 180 min               | 0.545                         | 0.420                    | 0.664                    | 1.30            | 0.82            | 0.777                                    | p<0.05                        |
| Cortisone, 240 min               | 0.433                         | 0.389                    | 0.616                    | 1.11            | 0.70            | 0.599                                    | p<0.05                        |
| Duration of diabetes             | -0.353                        | 0.465                    | 0.736                    | -0.76           | -0.48           | -0.601                                   | NS                            |
| UFC/24 hours                     | 0.399                         | 0.292                    | 0.462                    | 1.37            | 0.86            | 0.688                                    | p<0.05                        |
| Basal ACTH                       | 0.457                         | 0.260                    | 0.412                    | 1.75            | 1.11            | 0.777                                    | p<0.01                        |
| ACTH, peak                       | 0.485                         | 0.195                    | 0.309                    | 2.48            | 1.57            | 0.825                                    | p<0.01                        |
| Aldosterone/PRA                  | 0.288                         | 0.129                    | 0.205                    | 2.23            | 1.41            | 0.531                                    | p<0.01                        |
| Basal ACTH after dexam           | 0.489                         | 0.159                    | 0.251                    | 3.09            | 1.95            | 0.832                                    | p<0.01                        |

$R^2_{a)}$ 49.5 %  
$Q^2_{b)}$ 39.5%

$^a$R$^2$ is the percent of variation of dependent variable explained by the model; $^b$Q$^2$ is the percent of variation of dependent variable predicted by the model according to cross validation; the model was created from all steroids and related substances investigated but only the relevant independent variables remained in the final model (for details see Statistical data analysis).

Correlation of area under the curve (AUC) for F and F to E ratio

Calculated AUC for F and F to E ratio have a normal Gaussian distribution and therefore were used for correlation analysis (Pearson’s test) with parameters used in the ANOVA analysis. Correlation analysis did not reveal any significant relations to AUC for F including relationship
between AUC for F and serum peak F response in the LDST.

The significant correlations were found only between AUC for F/E ratio and suppressed basal level of ACTH after dexamethasone (r = -0.8862, p<0.001).

Discussion

During the whole cortisone acetate test, levels of F remained significantly higher in DM1. When analyzing F response in diabetics by multifactorial ANOVA, it appeared that the only significant relationships were found in the 120th min. It is not therefore surprising that correlation analysis did not reveal any significant relations to AUC for F. It indicates that with the exception of F value at 120th min, the concentrations of serum F in cortisone acetate test in DM1 patients is probably influenced by other, more significant factors than by 11β-HSD1 activity. These factors are studied in the literature and include the metabolism of cortisol by 5α and 5β reductases. These enzymes convert cortisol to its tetrahydro-metabolites. The factors influencing the 5α and 5β reductases are still studied, the most important regulators appear to be insulin and lipids (Wake et al. 2004).

The conclusion that F value at 120th min is really influenced by 11β-HSD1 activity is supported by several important relationships. At first, there is negative correlation between F value at 120th min and insulin dose/kg/24 hours, which is in full agreement with the data in the literature on 11β-HSD1 inhibition by insulin (Putignano et al. 2004). Taking into account absence of correlation of F value at 120th min to HbA1C and basal glycemia before dexamethasone suppression, the relation of insulin dose to 11β-HSD1 activity appears as a factor independent on metabolic control. It should be mentioned here that all the diabetics studied were treated for a long time by an intensive insulin system basal bolus. It is known that insulin in part activates IGF-1 receptors, which also down regulate activity of 11β-HSD1 (Moore et al. 1999, Stewart et al. 2001, Putignano et al. 2004, Agha et al. 2007). On the other hand, a negative correlation was found between F values at 120th min and dexamethasone-suppressed basal glycemia. It could be explained by manifestation of an operative short-time down regulation of 11β-HSD1 activity, under enhanced effect of dexamethasone on liver gluconeogenesis with consequent hyperglycemia. Down regulation of 11β-HSD1 activity could decrease intrahepatal cortisol formation and prevent hyperglycemia worsening. It may be speculated that failure of this down regulation under a long-term glucocorticoid treatment may contribute to the steroid induced diabetes mellitus, analogically to failure of 11β-HSD1 down regulation described for rise of diabetes mellitus type 2 (Putignano et al. 2004, Valsamakis et al. 2004).

A comment is needed for a lack of relation between F response in cortisone acetate test and the peak cortisol response at LDST. This finding resembles the results of recent study of Paisley, who found that even subnormal peak cortisol response after hypoglycemia need not mean decreased all-day F production and should not be an automatic indication for glucocorticoid replacement therapy (Paisley et al. 2009). In our group of low responders in LSDT no significant differences occurred in metabolic control or daily dose of insulin as well (Šimůnková et al. 2010).

As the most significant factors relating with the F to E ratio response during cortisone acetate test in DM1 identified by multifactorial ANOVA were the dexamethasone-suppressed ACTH values, measured immediately before starting of cortisone acetate test, and the ratio of aldo to PRA together with UFC per 24 hours from the Day 1, i.e. before administration of dexamethasone. The negative relationships of these parameters to F/E ratio were significant for almost all the times of the cortisone acetate test, namely at 60th, 120th, 180th, and 240th min. As for dexamethasone-suppressed ACTH values, the results points to the fact that the more pronounced is the hypothalamo-pituitary-adrenal axis suppression, the more intensive conversion of cortisone to cortisol occurs and vice versa. This conclusion is supported by very tight correlations of dexamethasone-suppressed values of ACTH to AUC for F to E ratio (r = -0.8862). Moreover, additional correlations of F to E ratio with non-suppressed values of aldo/PRA ratio and UFC are indicative of compensatory increased hepatal F production not only under short term dexamethasone-suppressed HPA activity, but also at the situation of long-lasting decreased adrenal functional capacity.

The lowered aldo/PRA ratio is believed to be the most sensitive parameter of adrenal function in contrast to UFC per 24 hours, which repeatedly appeared unreliable (Ten et al. 2001, Paisley et al. 2009). Despite this fact, multifactorial ANOVA has proven that decreasing UFC /24 hours before dexamethasone administration is accompanied by increased E to F conversion and vice versa.

A positive relationship between the F to E ratio and DHEA-S level (followed in women only) may demonstrate that the increased conversion depends also
on the sufficient DHEA-S level.

It can be concluded that the examination of peripheral metabolism of F assessed by cortisone acetate test in patients with DM1 showed changes, which suggest the participation of 11β-HSD1 in the mechanism of tissue compensation of cortisol supply alteration. Our data suggest that the compensation involves 1) increase of cortisone conversion to cortisol at subclinical hypocorticalism; however increasing daily dose of insulin decreases this conversion and vice versa 2) tissue protection by decreasing conversion of cortisone to cortisol in the liver after administration of exogenous glucocorticoids.

Conflict of Interest
There is no conflict of interest.

Acknowledgements
This article is dedicated to important life anniversary of prof. Luboslav Stárka. We thank the study participants and our excellent research nurses. We also thank the members of our steroid research group. The study was supported by grant NT 11 277 of the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR).

References

AGHA A, MONSON JP: Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axix. Clin Endocrinol (Oxf) 66: 459-65, 2007.

ANDREWS RC, HERLIHY O, LIVINGSTONE DEW, ANDREW R, WALKER BR: Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance. J Clin Endocrinol Metab 87: 5587-5593, 2002.

FIILIPOVIC D, GAVRIOLOVIC L, DRONJAK S, RADOJCIC MB: Liver glucocorticoid receptor and heat shock protein 70 levels exposed to different stress model. Physiol Res 57: 205-213, 2008.

MAI K, ANDRES, BOBBERT J, MASER-GLUTH TC, MOHLI M, BAHR V, PFEIFFER AF, SPRANGER J, DIEDERICH S: Rosiglitazone decreases 11 beta-hydroxysteroid dehydrogenace type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 67: 419-425, 2007.

MOORE JS, MONSON JP, KALTSAS GP, PUTIGNANO P, WOOD PJ, SHEPPARD MC, BESSER GM, TAYLOR NF, STEWART PM: Modulation of 11 beta-hydroxysteroid dehydrogenase isoenzymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84: 4172-4177, 1999.

PAISLEY AN, ROWLES SV, BRANDON D, TRAINER PJ: A Subnormal Peak Cortisol Response to Stimulation Testing Does Not Predict a Subnormal Cortisol Production Rate. J Clin Endocrinol Metab 94: 1757-1760, 2009.

PUTIGNANO P, PECORI GIRALDI F, CAVAGNINI F: Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J Endocrinol Invest 27: 969-974, 2004.

RASK E, WALKER BR, SODERBERG S, DAWN E, LIVINGSTONE DEW, ELISASSON M, JOHNSON O, ANDREW R, OLSSON T: Tissue-Specific Changes in Peripheral Cortisol Metabolism in Obese Women: Increased Adipose 11beta Hydroxysteroid Dehydrogenase Type 1 Activity. J Clin Endocrinol Metab 87: 3330-3336, 2002.

REICHARDT MH, BRONCHE F, BAUER A, SCHULZ G: Molecular genetic analysis of glucocorticoids signaling using the Cre/ioxP systém. Biol Chem 381: 961-964, 2000.

REYNOLDS RM, WALKER BR: Human insulin resistance: the role of glucocorticoids. Diab Obes Metab 5: 5-12, 2003.

ŠIMŮNKOVÁ K, HAMPL R, HILL M, KŘÍŽ L, HRDÁ P, JANÍČKOVÁ-ŽDÁRSKÁ D, ZAMRAZIL V, VRBÍKOVÁ J, VONDRA K: Adrenocortical function in young adults with diabetes mellitus type 1. J Steroid Biochem Mol Biol 122: 35-41, 2010.

STEWART PM, BOULTON A, KUMAR S, CLARK PMS, SHACKLETON CH: Cortisol Metabolism in Human Obesity: Impaired Cortisone - Cortisol Conversion in Subjects with Central Adiposity. J Clin Endocrinol Metab 84: 1022-1027, 2005.
STEWARD PM, TOOGOOD AA, TOMLINSON JW: Growth hormone, insulin-like growth factor-1 and the cortisol-cortisone shuttle. *Horm Res* **56** (Suppl 1): 1-6, 2001.

TOMLINSON JW, WALKER EA, BUJALSKA I, DRAPER N, LAVERY GG, COOPER MS, HEWISON M, STEWARD PM: 11ß-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. *Endocrine Rev* **25**: 831-866, 2004.

TEN S, NEW M, MACLAREN N: Clinical Review 130: Addison’s Disease 2001. *J Clin Endocrinol Metab* **86**: 2909-2922, 2001.

VALSAMAKIS G, ANWAR A, TOMLINSON JW, SHACKLETON CHL, MCTERNAN PG, CHETTY R, WOOD PJ, BANERJEE AK, HOLDER G, BARNETT AH, STEWARD PM, KUMA S: 11ß-hydroxysteroid dehydrogenase type 1 in lean and obese males with type 2 diabetes mellitus. *J Clin Endocrinol Metab* **89**: 4755-4761, 2004.

WAKE DJ, WALKER BR: 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. *Mol Cell Endocrinol* **215**: 45-54, 2004.

WESTERBACKA J, YKI-JARVINEN H, VEHKAVAARA S, HAKKINEN AM, ANDREW R, WAKE DJ, SECKL JR, WALKER BR: Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. *J Clin Endocrinol Metab* **88**: 4924-4931, 2003.